Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
7195 participants
OBSERVATIONAL
2011-11-30
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IPDI EF HFA-BDP
Patients initiating inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
No interventions assigned to this group
IPDI FP
Patients initiating inhaled corticosteroid therapy as FP via pMDI at the index date
No interventions assigned to this group
IPDI NEF HFA-BDP
Patients initiating inhaled corticosteroid therapy as non-extra-fine HFA-BDP via pMDI at the index date
No interventions assigned to this group
IPDA EF HFA-BDP
Patients increasing inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
No interventions assigned to this group
IPDA FP
Patients increasing inhaled corticosteroid therapy as FP MDI at the index date
No interventions assigned to this group
IPDA NEF HFA-BDP
Patients initiating inhaled corticosteroid therapy as non-extra-fine HFA-BDP via pMDI at the index date
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current smokers - explicitly coded in patient records or captured in patient questionnaires
* Evidence of asthma diagnosis and current therapy: ≥2 prescriptions for asthma at different points in time during the baseline year ± a diagnostic code for asthma
* On-going asthma therapy: ≥2 prescription for ICS during the outcome period (i.e. ≥1 prescription in addition to IPD prescription)
* ≥2 years continuous data (i.e. ≥1 year of baseline plus ≥1 year of outcome data)
Exclusion Criteria
* Any chronic respiratory disease other than asthma
* Are prescribed:
* Maintenance oral steroid therapy during the baseline year
* Combination ICS/long-acting beta agonist (LABA) therapy during baseline year or at IPD
* Multiple ICS prescriptions at IPD or immediately before .
16 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY
Research in Real-Life Ltd
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
David Price
Professor David Price
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Professor Price
Role: PRINCIPAL_INVESTIGATOR
University of Aberdeen
References
Explore related publications, articles, or registry entries linked to this study.
Price D, Martin RJ, Barnes N, Dorinsky P, Israel E, Roche N, Chisholm A, Hillyer EV, Kemp L, Lee AJ, von Ziegenweidt J, Colice G. Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study. J Allergy Clin Immunol. 2010 Sep;126(3):511-8.e1-10. doi: 10.1016/j.jaci.2010.06.040. Epub 2010 Aug 9.
Barnes N, Price D, Colice G, Chisholm A, Dorinsky P, Hillyer EV, Burden A, Lee AJ, Martin RJ, Roche N, von Ziegenweidt J, Israel E. Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study. Clin Exp Allergy. 2011 Nov;41(11):1521-32. doi: 10.1111/j.1365-2222.2011.03820.x. Epub 2011 Jul 14.
Hansell A, Hollowell J, Nichols T, McNiece R, Strachan D. Use of the General Practice Research Database (GPRD) for respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4). Thorax. 1999 May;54(5):413-9. doi: 10.1136/thx.54.5.413.
Ivanova JI, Birnbaum HG, Hsieh M, Yu AP, Seal B, van der Molen T, Emani S, Rosiello RA, Colice GL. Adherence to inhaled corticosteroid use and local adverse events in persistent asthma. Am J Manag Care. 2008 Dec;14(12):801-9.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Practice Research Database
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R01911
Identifier Type: -
Identifier Source: org_study_id